ISTO Biologics

St. Louis, United States Founded: 1997 • Age: 29 yrs
Developer of treatments for cartilage and bone problems

About ISTO Biologics

ISTO Biologics is a company based in St. Louis (United States) founded in 1997.. ISTO Biologics has raised $50.76 million across 15 funding rounds from investors including HHS, NIST and Life Sciences Partners. ISTO Biologics has completed 3 acquisitions, including Progenicare, TheraCell and Theracell. ISTO Biologics offers products and services including Magellan®, Influx™, InQu®, and Precise™. ISTO Biologics operates in a competitive market with competitors including Kuros Biosciences, OssDsign, BONESUPPORT, Askel Healthcare and Renovos, among others.

  • Headquarter St. Louis, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Isto Technologies Ii, Llc,
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $50.76 M (USD)

    in 15 rounds

  • Latest Funding Round
    $1.2 M (USD), Grant

    Jul 29, 2015

  • Investors
    HHS

    & 6 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
    Progenicare

    & 2 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of ISTO Biologics

ISTO Biologics offers a comprehensive portfolio of products and services, including Magellan®, Influx™, InQu®, and Precise™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Device for creating platelet-rich plasma and bone marrow therapies.

Allograft products for bone grafting and tissue repair.

Biosynthetic bone graft for faster fusion and healing.

System for targeted leukocyte-rich or poor platelet-rich plasma.

People of ISTO Biologics
Headcount 50-200
Employee Profiles 19
Employee Profiles
People
Taylor Hatjes
Territory Sales Director
People
Jason Slade Dc
Area Vice President Of Sales
People
Jerry Keefe
Vice President Operations
People
J.r. Mikulak
Area Vice President - International (ous)

Unlock access to complete

Funding Insights of ISTO Biologics

ISTO Biologics has successfully raised a total of $50.76M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $1.2 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 15
  • Last Round Grant — $1.2M
  • First Round

    (12 Oct 2001)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2015 Amount Grant - ISTO Biologics Valuation

investors

Jul, 2015 Amount Grant - ISTO Biologics Valuation

investors

HHS
Dec, 2014 Amount Series E - ISTO Biologics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ISTO Biologics

ISTO Biologics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, NIST and Life Sciences Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Life-Sciences focused early & growth stage VC firm investing in the US & Europe
Founded Year Domain Location
Private equity investments in life sciences businesses are managed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ISTO Biologics

ISTO Biologics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Progenicare, TheraCell and Theracell. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Stem cell therapies for regenerative healthcare needs are developed.
2012
Cell and gene therapy products and orthopedic services are provided.
2008
Allograft solutions for spinal surgery are provided by TheraCell.
2008
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - ISTO Biologics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Isto Biologics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ISTO Biologics

ISTO Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kuros Biosciences, OssDsign, BONESUPPORT, Askel Healthcare and Renovos, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of smart solutions for bone disease management
domain founded_year HQ Location
Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma
domain founded_year HQ Location
Injectable synthetic bone substitutes are developed for fracture treatment.
domain founded_year HQ Location
Regenerative medicines for cartilage and bone tissue regeneration are developed.
domain founded_year HQ Location
Renovos is focused on regenerative medicine and therapeutic delivery.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Isto Biologics

Frequently Asked Questions about ISTO Biologics

When was ISTO Biologics founded?

ISTO Biologics was founded in 1997 and raised its 1st funding round 4 years after it was founded.

Where is ISTO Biologics located?

ISTO Biologics is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.

Is ISTO Biologics a funded company?

ISTO Biologics is a funded company, having raised a total of $50.76M across 15 funding rounds to date. The company's 1st funding round was a Series E of $2.46M, raised on Oct 12, 2001.

What does ISTO Biologics do?

ISTO Biologics is an orthobiologics company developing treatments for cartilage and bone repair. Orthobiologics is a technique that uses a combination of biomaterials and cell-based therapies to promote healing and repair tissues. In biomaterials, ISTOs patented biosynthetic platform uses a mixture of synthetic polylactide-co-glycolide (PLGA) and hyaluronic acid (HyA) to make tissue scaffolds. This PLGAHyA combination scaffold supports bone formation. Their 2nd product is Influx, which is an osteoinductive bone graft, made of demineralized human trabecular bone, for spinal fusions and orthopedic applications. Their 3rd product line is called CellPoint and is a concentrated Bone Marrow aspirate system. The kit includes a cell separation kit and the accessories required to aspirate and concentrate bone marrow.

Who are the top competitors of ISTO Biologics?

ISTO Biologics's top competitors include BONESUPPORT, OssDsign and Kuros Biosciences.

What products or services does ISTO Biologics offer?

ISTO Biologics offers Magellan®, Influx™, InQu®, and Precise™.

How many acquisitions has ISTO Biologics made?

ISTO Biologics has made 3 acquisitions, including Progenicare, TheraCell, and Theracell.

Who are ISTO Biologics's investors?

ISTO Biologics has 7 investors. Key investors include HHS, NIST, Life Sciences Partners, NIH SBIR/STTR, and USPTO.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available